Search

Author/Creator O'Connell, Joseph

1. Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). (April 2017)

Authors:
Kim, Dong-Wan; Garon, Edward B.; Jatoi, Aminah; Keefe, Dorothy M.; Lacouture, Mario E.; Sonis, Stephen; Gernhardt, Diana; Wang, Tao; Giri, Nagdeep; Doherty, Jim P.; Nadanaciva, Sashi; O'Connell, Joseph; Sbar, Eric; Cho, Byoung Chul
Journal:
Lung cancer
Issue:
Volume 106(2017)
Page Start:
76
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer. (January 2013)

Authors:
Boyer, Michael; Jänne, Pasi Antero; Mok, Tony; O'Byrne, Kenneth; Paz-Ares, Luis; Ramalingam, Suresh S; Liang, Jane; Taylor, Ian; Campbell, Alicyn; O'Connell, Joseph; Letrent, Stephen; Antic, Vladan
Journal:
Clinical investigation
Issue:
Volume 3:Number 1(2013)
Page Start:
29
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer. (January 2013)

Authors:
Boyer, Michael; Jänne, Pasi Antero; Mok, Tony; O'Byrne, Kenneth; Paz-Ares, Luis; Ramalingam, Suresh S; Liang, Jane; Taylor, Ian; Campbell, Alicyn; O'Connell, Joseph; Letrent, Stephen; Antic, Vladan
Journal:
Clinical investigation
Issue:
Volume 3:Number 1(2013)
Page Start:
29
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗